International Urology and Nephrology

, Volume 49, Issue 8, pp 1433–1437 | Cite as

Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study

  • Hua Zhou
  • Min Yang
  • Min Li
  • Li Cui
Nephrology – Original Paper



Bone metabolism disorder is often associated with cardiovascular calcification in patients with chronic kidney disease (CKD). Sclerostin, a novel candidate protein, has been identified to be involved in the bone–vascular axis. The aims of the current investigation were to assess vessel sclerostin expression and its relationship with circulating sclerostin levels.


A cross-sectional observational study was conducted from January 2012 to December 2014. Thirty-two predialysis patients with CKD stage 5 who received arteriovenous fistula (AVF) operations were enrolled in this study. Radial arteries were collected and paraffin-embedded during the AVF operation, followed by immunohistochemical staining for sclerostin expression. In addition, serum sclerostin levels were measured by the enzyme-linked immunosorbent assay.


The prevalence of positive sclerostin staining in the radial arteries was 56.25%. Sclerostin expression was localized in the artery media layer. Serum sclerostin levels in patients with positive sclerostin expression were much higher than in those with negative expression (p = 0.018). Multivariate logistic regression analyses including potential confounders as age, gender, systolic blood pressure (BP), diastolic BP, serum sclerostin, corrected calcium (Ca), phosphate (P), Ca × P product, alkaline phosphatase, intact parathyroid hormone, and estimated glomerular filtration rate showed that only serum sclerostin levels were closely related to vessel sclerostin expression (p = 0.025). The area under the curve of serum sclerostin levels for predicting positive vessel sclerostin expression was 0.742 with 61.1% sensitivity and 85.7% specificity (p  = 0.008). The cutoff point for vessel sclerostin expression of serum sclerostin was 1591.53 pg/mL.


Positive expression of sclerostin in the radial artery media layer was related to high serum sclerostin levels. Sclerostin may act as both a local and systemic regulator involved in vascular calcification.


Chronic kidney disease Radial artery Sclerostin Vascular calcification 



This study was funded by Youth Talent Programme of Changzhou Government Healthy Service (No. QN201402). The authors thank Zhong Xue for making substantial contributions to data collection.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Russo D, Corrao S, Battaglia Y et al (2011) Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int 80(1):112–118CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gauthier-Bastien A, Ung RV, Larivière R et al (2014) Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens 36(3):173–180CrossRefPubMedGoogle Scholar
  3. 3.
    Davies MR, Hruska KA (2001) Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int 60(2):472–479CrossRefPubMedGoogle Scholar
  4. 4.
    Demer LL, Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117(22):2938–2948CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gaudio A, Privitera F, Battaglia K et al (2012) Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2diabetes mellitus. J Clin Endocrinol Metab 97(10):3744–3750CrossRefPubMedGoogle Scholar
  6. 6.
    Brandenburg VM, Kramann R, Koos R et al (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kramann R, Brandenburg VM, Schurgers LJ et al (2013) Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 28:856–868CrossRefPubMedGoogle Scholar
  8. 8.
    Zhu D, Mackenzie NC, Millán JL et al (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Qureshi AR, Olauson H, Witasp A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88(6):1356–1364CrossRefPubMedGoogle Scholar
  10. 10.
    Kanbay M, Siriopol D, Saglam M et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 99(10):E1854–E1861CrossRefPubMedGoogle Scholar
  11. 11.
    Morena M, Jaussent I, Dupuy AM et al (2015) Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 30(8):1345–1356CrossRefPubMedGoogle Scholar
  12. 12.
    Pelletier S, Confavreux CB, Haesebaert J et al (2015) Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int 26(8):2165–2174CrossRefPubMedGoogle Scholar
  13. 13.
    Claes KJ, Viaene L, Heye S et al (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98(8):3221–3228CrossRefPubMedGoogle Scholar
  14. 14.
    Balcı M, Kırkpantur A, Turkvatan A et al (2015) Sclerostin as a new key player in arteriovenous fistula calcification. Herz 40(2):289–297CrossRefPubMedGoogle Scholar
  15. 15.
    Kirkpantur A, Balci M, Turkvatan A et al (2015) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nefrologia 36(1):24–32CrossRefPubMedGoogle Scholar
  16. 16.
    Delanaye P, Krzesinski JM, Warling X et al (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128(1–2):127–134CrossRefPubMedGoogle Scholar
  17. 17.
    Yang CY, Chang ZF, Chau YP et al (2015) Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. Nephrol Dial Transplant 30(8):1356–1363CrossRefPubMedGoogle Scholar
  18. 18.
    Evenepoel P, Goffin E, Meijers B et al (2015) Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin Endocrinol Metab 100(12):4669–4676CrossRefPubMedGoogle Scholar
  19. 19.
    Lee YT, Ng HY, Chiu TT et al (2016) Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients. Clin Chim Acta 452:38–43CrossRefPubMedGoogle Scholar
  20. 20.
    Jean G, Chazot C, Bresson E et al (2016) High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 132(3):181–190CrossRefPubMedGoogle Scholar
  21. 21.
    Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Drake MT, Srinivasan B, Mödder UI et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056–5062CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cejka D, Marculescu R, Kozakowski N et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99(1):248–255CrossRefPubMedGoogle Scholar
  24. 24.
    Kanbay M, Solak Y, Siriopol D et al (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48(12):2029–2042CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  1. 1.Department of NephrologyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina
  2. 2.Department of UrologyThe Third Affiliated Hospital of Soochow UniversityChangzhouChina

Personalised recommendations